Story perspectives

CSL Shares Plunge 20% After $5 B Impairments

5/12/2026

Summary

CSL Cuts Guidance

CSL Ltd (ASX: CSL) fell 20.29% to AUD 95.56 on May 11, 2026 after cutting FY26 guidance and flagging $5 billion of impairments.
It projects FY26 revenue of $15.2 billion, NPATA of $3.1 billion, and $650 million of headwinds from U.S. immunoglobulin, China albumin and other factors.
Interim CEO Gordon Naylor said growth initiatives are working but benefits will take longer.
CSL targets $500-$550 million of savings by FY2028 and will reinvest part of the savings into growth.

Summary

CSL Recognises Impairments

CSL will recognise $5 billion of impairments in FY26-FY27 from CSL Vifor assets and plant.
CSL continues hunt for an executive, with interim CEO Gordon Naylor staying on the board as a director.
Andy Schmeltz retires as chief commercial officer, with Diego Sacristan assuming the role on 1 July 2026.
Management cites a $150 million revenue drag from Middle East conflict and notes demand growth with a 49% decline versus a 6% rise in S&P/ASX 200.

History

Historical Context

CSL Limited’s multi-billion-dollar impairment announced in May 2026 echoes the massive write-downs seen during the 2008 global financial crisis, when the U.S. Treasury launched a $700 billion Troubled Asset Relief Program to shore up banks. Both episodes show how sharp credit contractions force biotech firms and other corporates to cut costs and restructure.

1 of 3

CSL Cuts Guidance

CSL Ltd (ASX: CSL) fell 20.29% to AUD 95.56 on May 11, 2026 after cutting FY26 guidance and flagging $5 billion of impairments.
It projects FY26 revenue of $15.2 billion, NPATA of $3.1 billion, and $650 million of headwinds from U.S. immunoglobulin, China albumin and other factors.
Interim CEO Gordon Naylor said growth initiatives are working but benefits will take longer.
CSL targets $500-$550 million of savings by FY2028 and will reinvest part of the savings into growth.

1 / 3